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463Vasodilator Stress Perfusion CMR Imaging Is Feasible and
Prognostic in Obese PatientsOBJECTIVES This study sought to determine feasibility and prognostic performance of stress cardiac mag-
netic resonance (CMR) in obese patients (body mass index [BMI] $30 kg/m2).
BACKGROUND Current stress imaging methods remain limited in obese patients. Given the impact of the
obesity epidemic on cardiovascular disease, alternative methods to effectively risk stratify obese patients are
needed.
METHODS Consecutive patients with a BMI $30 kg/m2 referred for vasodilating stress CMR were followed
for major adverse cardiovascular events (MACE), deﬁned as cardiac death or nonfatal myocardial infarction.
Univariable and multivariable Cox regressions for MACE were performed to determine the prognostic associ-
ation of inducible ischemia or late gadolinium enhancement (LGE) by CMR beyond traditional clinical risk
indexes.
RESULTS Of 285 obese patients, 272 (95%) completed the CMR protocol, and among these, 255 (94%)
achieved diagnostic imaging quality. Mean BMI was 35.4  4.8 kg/m2, with a maximum weight of 200 kg. Rea-
sons for failure to complete CMR included claustrophobia (n ¼ 4), intolerance to stress agent (n ¼ 4), poor
gating (n ¼ 4), and declining participation (n ¼ 1). Sedation was required in 19 patients (7%; 2 patients with
intravenous sedation). Sixteen patients required scanning by a 70-cm–bore system (6%). Patients without induc-
ible ischemia or LGE experienced a substantially lower annual rate of MACE (0.3% vs. 6.3% for those with
ischemia and 6.7% for those with ischemia and LGE). Median follow-up of the cohort was 2.1 years. In a multi-
variable stepwise Cox regression including clinical characteristics and CMR indexes, inducible ischemia (hazard
ratio 7.5; 95% conﬁdence interval: 2.0 to 28.0; p ¼ 0.002) remained independently associated with MACE. When
patients with early coronary revascularization (within 90 days of CMR) were censored on the day of revascular-
ization, both presence of inducible ischemia and ischemia extent per segment maintained a strong association
with MACE.
CONCLUSIONS Stress CMR is feasible and effective in prognosticating obese patients, with a very low
negative event rate in patients without ischemia or infarction. (J Am Coll Cardiol Img 2014;7:462–72)
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A B B R E V I A T I O N S
A N D A C R O N YM S
BMI = body mass index
CAD = coronary artery dise
CTA = computed tomogra
angiography
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
HR = hazard ratio
IQR = interquartile range
LGE = late gadolinium
enhancement
LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac events
MI = myocardial infarction
PET = positron emission
tomography
SPECT = single-photon em
computed tomography
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464mainstay of current clinical practice, single-photon
emission computed tomography (SPECT) nuclear
perfusion imaging may be hampered by attenuation
artifacts and reduced signal-to-noise ratio, limit-
ing diagnostic accuracy in obese patients (4–9). The
prognostic impact of a negative nuclear scan may be
associated with BMI. In one study, a normal
perfusion scan was associated with a nearly 1.7% risk
of death at 1 year (9). Although positron emission
tomography (PET) overcomes many of these
challenges, as a result of superior diagnostic and
prognostic performance in obese patients (10),
ionizing radiation, radiotracer availability, and cost
pose important limitations to its widespread
adoption.ase
phy
issionStress cardiac magnetic resonance
(CMR) can assess ventricular function,
stress and rest perfusion, and viability
within a single examination (11). Relative
to alternative techniques, stress CMR
has high spatial and temporal resolution
and is not limited by acoustic windows or
image acquisition. However, concerns
over feasibility in obese patients because
of claustrophobia and safety monitoring
have limited the adoption of stress CMR
in this important, burgeoning popula-
tion. To address these fundamental con-
cerns, we sought to determine the
feasibility of stress CMR in obese pa-
tients and the prognostic impact of stress
CMR results on cardiovascular events.
METHODS
Study population. We identiﬁed patients
with a BMI $30 kg/m2 from consecutive
patients $18 years of age referred toBrigham and Women’s Hospital between December
2001 and August 2011 for the assessment of sus-
pected myocardial ischemia. Exclusion criteria
consisted of known hypersensitivity to gadolinium-
based contrast agents, glomerular ﬁltration rate
<30 ml/min/1.73 m2, pregnancy, weight >250 kg
(because of table limitations), acute myocardial
infarction (MI), hemodynamic instability, presence
of metallic hazards, and history of asthma or
bronchospastic disease. Patients with atrial ﬁbril-
lation at the time of CMR were included in the
study. Clinical data were collected by medical his-
tory and clinical examination on the day of stress
CMR by a trained physician using standardized
criteria. Our institutional review board approved
follow-up of clinical events, and all participatingpatients gave written informed consent for stress
CMR.
Cardiac magnetic resonance. Patients were scanned
with a 60-cm–bore, 1.5-T magnet (Signa CV/i,
GE Medical Systems, Milwaukee, Wisconsin) with
an 8-element phased-array coil before 2006 and
with a 3.0-T scanner (60-cm–bore Magnetom Trio
[TIM system], Siemens, Erlangen, Germany) with
a 16-element phased array coil after 2006. With the
availability of a wide-bore scanner (70-cm bore
diameter, 3.0-T Magnetom Verio, Siemens) in
2007, this scanner was used when requested by
the referral clinician, signiﬁcant patient history of
claustrophobia from pre-CMR screening, or
failure to perform CMR at either 60-cm–bore
scanners. Oral sedation (diazepam 0.5 to 1.0 mg)
was given 15 to 20 min before CMR examination
where necessary. Intravenous conscious sedation
was offered if oral sedation failed to control
claustrophobic symptoms (both via short-acting
benzodiazepine, intravenous or oral; or fentanyl,
intravenous). The stress CMR protocol was op-
timized for obese patients via: 1) lateral place-
ment of 1 of the electrocardiographic leads to
improve gating signal; 2) increasing ﬁeld of view
with real-time adjustment to prevent wrap arti-
fact; and 3) dynamic gradient echo shimming
around cardiac structures before cine steady-state
free precession imaging. All patients were
instructed to refrain from caffeine for 24 h and to
fast for at least 6 h before the CMR examination.
Our CMR protocol included localizers, cine
function, stress and rest perfusion, and late gad-
olinium enhancement (LGE) imaging. A 12-lead
electrocardiogram was performed both before and
following CMR examination. Cine images were
acquired in both short-axis (contiguous 8-mm
slices) and long-axis (4-chamber, 2-chamber,
and 3-chamber) views of the left ventricle with
steady-state free precession cine imaging (repeti-
tion time 3.4 ms; echo time 1.2 ms; matrix 256 
256; ﬁeld of view 34 to 40 cm).
Vasodilator stress was achieved using either in-
travenous adenosine (Adenoscan, Astellas Pharma
US, Deerﬁeld, Illinois) (n ¼ 149 [58%]) infused at a
rate of 140 mg/kg/min over 6 min or regadenoson
(Lexiscan, Astellas Pharma US) (n ¼ 106 [42%]) as
an intravenous bolus of 0.4 mg, hand-injected over
10 s. Myocardial perfusion images for both stress
and rest were acquired with a saturation-prepared,
single-shot spoiled gradient echo sequence (repeti-
tion time 6 ms; echo time 2.3 ms; slice thickness
8 mm) during bolus injection of 0.1 mmol/kg intra-
venous gadolinium (Magnevist, Bayer HealthCare,
Figure 1. Feasibility of CMR in Obese Patients
The pie chart illustrates the feasibility of performing stress perfusion cardiac
magnetic resonance (CMR) in the retrospective cohort of obese patients. A
total of 285 patients were referred for CMR, 13 (4.6%) of whom failed largely as
the result of claustrophobia, intolerance to vasodilator agent, and poor elec-
trocardiographic gating. Of the remaining 272 patients, 255 (94%) were found
by 2 experienced CMR observers to have images of diagnostic quality. Sedation
to perform CMR was required in 19 (6.7%) patients.
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465Wayne, New Jersey) at 4 to 5 ml/s, followed by
a saline ﬂush. Myocardial perfusion images were
acquired in 3 short-axis (basal, mid, and apical) and
1 long-axis (4-chamber) view (for acquisitions on
the Siemens scanners). LGE was performed using a
standard inversion recovery gradient echo sequence
in short- and long-axis slices 10 to 15 min after
rest perfusion imaging (with total gadolinium
dose 0.20 mmol/kg, with appropriate TI time to
null normal myocardium). Vital signs, electrocar-
diography, and respiration were monitored contin-
uously throughout the CMR scan. Blood pressure
was measured with noninvasive sphygmomanom-
etry before and following administration of the
vasodilator agent. All images were acquired at end-
expiration with electrocardiographic gating (with
provisional pulse gating for electrocardiographic
gating failure).
CMR analysis. Perfusion images were interpreted by
2 experienced observers (R.Y.K. and B.H.) blinded
to clinical and follow-up data. CMR images were
analyzed by standard post-processing techniques on
an ofﬂine workstation (Mass Clinical 7.4, Medis,
Leiden, the Netherlands). Ventricular volumes, func-
tion, and mass were quantiﬁed by previously published
techniques (12). Cine wall motion was assessed in
a 17-segment American Heart Association model,
and perfusion imaging was assessed in a 16-segment
model (13). Inducible ischemia was deﬁned as any
stress perfusion defect that: 1) remained dark and
persisted for at least 3 phases beyond peak contrast
enhancement; 2) was at least 1 pixel in thickness;
and 3) followed a coronary distribution. These
criteria are similar to multicenter published studies
(14,15). Inducible ischemia was deﬁned as the
presence of any segmental subendocardial stress
perfusion defect in the absence of LGE in the same
segment. Therefore, segments with LGE and
matching stress perfusion defects were not counted
as “inducible ischemia.” LGE was evaluated qual-
itatively (presence or absence) and quantitatively
using a signal intensity threshold of $2 SD above
remote normal myocardium, as previously pub-
lished (12).
Clinical outcomes. Patient follow-up was obtained
through review of the electronic medical record,
followed by a mailed standard questionnaire or
scripted telephone interview by trained study
personnel (when medical records were not avail-
able). Mortality was conﬁrmed by the Social
Security Death Index. Our primary outcome was
a composite of cardiac death or nonfatal MI,
deﬁned as major adverse cardiac events (MACE).
Our secondary outcome was a composite ofall-cause mortality or nonfatal MI. Nonfatal MI
was deﬁned as a new clinical presentation of chest
pain or dyspnea with an elevation of cardiac bio-
markers (>99th percentile of the upper limits of
normal) in a temporal pattern consistent with an
acute MI (16).
Statistics. Parametric continuous data were ex-
pressed as means with SD, whereas nonpara-
metrically distributed continuous data were
presented as medians with interquartile range
(IQR). Categorical variables were expressed as
counts with percentages. Comparison between
groups was performed with a 2-sample Student t
test for continuous, normal data, and Wilcoxon
rank sum test for continuous, non-normal data.
The Fisher exact test was used to compare strat-
iﬁed categorical data. MACE-free survival strat-
iﬁed by the presence or absence of inducible
ischemia was estimated by the Kaplan-Meier
method and compared using a log-rank test.
Univariable Cox regression models were used to
estimate unadjusted hazard of MACE for clinical
and CMR characteristics. The independent
prognostic value of inducible ischemia for MACE
was evaluated using a multivariable Cox model
constructed by inclusion of signiﬁcant covariates
on univariable screen in a stepwise selection al-
gorithm (p < 0.05 for model entry and retention).
All clinical covariates and CMR indexes (left
ventricular and right ventricular function, mass,
volumes, wall motion, and perfusion results) were
included as potential covariates in the multivari-
able model. We assessed for the presence of
Table 1. Patient Characteristics for All Patients and Patients With and Without
Inducible Ischemia
Inducible
Ischemia L
(n [ 180)
Inducible
Ischemia D
(n [ 75) p Value
Age, yrs, median (IQR) 54 (15) 61 (15) <0.0001
Male 78 (43) 23 (31) 0.07
Body mass index, kg/m2, median (IQR) 34 (7) 34 (5) <0.05
Past history
Diabetes mellitus 51 (28) 31 (41) 0.06
Hypertension 115 (64) 56 (75) 0.14
Current or previous smoking 36 (20) 22 (29) 0.10
Hypercholesterolemia 95 (53) 55 (73) <0.01
Prior myocardial infarction 12 (7) 27 (36) <0.0001
Prior PCI 21 (12) 25 (33) <0.001
Prior CABG surgery 3 (2) 12 (16) <0.0001
Prior congestive heart failure 26 (14) 20 (27) <0.05
Symptomatic angina 40 (22) 33 (44) <0.001
Medications on presentation
Beta-blocker 92 (51) 53 (71) <0.01
Diuretic therapy 48 (27) 32 (43) <0.05
Aspirin 82 (46) 57 (76) <0.0001
ACE inhibitor 94 (52) 48 (64) 0.10
Statin 83 (46) 57 (76) <0.0001
Calcium channel blocker 37 (21) 11 (15) 0.30
Nitroglycerin 14 (8) 21 (28) <0.0001
Physical examination and electrocardiographic
features
Systolic BP, mm Hg, median (IQR) 135 (22) 129 (31) 0.01
Diastolic BP, mm Hg, median (IQR) 76 (17) 70 (18) 0.05
Heart rate, beats/min, median (IQR) 68 (20) 71 (17) 0.36
Presence of pathologic Q wave 13 (7) 17 (23) <0.01
Left bundle branch block 12 (7) 4 (5) 0.78
Left ventricular hypertrophy 14 (8) 5 (7) 1.0
Nonsinus rhythm 13 (7) 8 (11) 0.46
Resting ST-segment deviation 15 (8) 21 (28) <0.001
T-wave inversion 31 (17) 22 (29) 0.06
Values are median (IQR) or n (%).
þ ¼ with;  ¼ without; ACE ¼ angiotensin-converting enzyme; BP ¼ blood pressure; CABG ¼ coronary
artery bypass surgery; CMR ¼ cardiac magnetic resonance; IQR ¼ interquartile range; LGE ¼ late gado-
linium enhancement; LV ¼ left ventricle; PCI ¼ percutaneous coronary intervention; RV ¼ right ventricle.
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466collinearity amongst covariates in the ﬁnal
multivariable model. The proportional hazards
assumption for the multivariable model was
evaluated quantitatively by including time-
dependent covariates in the ﬁnal multivariable
Cox model. All statistical analyses were per-
formed using SAS version 9.2 (SAS Institute,
Cary, North Carolina). A 2-tailed p < 0.05 was
considered statistically signiﬁcant.RESULTS
Feasibility of stress CMR in obese patients. A total of
285 patients fulﬁlled the inclusion criteria for the
study. Thirteen patients (4.6%) were unable to
complete the stress CMR study (4 patients were
claustrophobic, 4 patients were intolerant of the
stress agent, 4 patients had poor gating, and 1 pa-
tient declined participation) (Fig. 1). Another
17 patients (6.0%) had nondiagnostic imaging
quality, with the remaining 255 patients comprising
the study cohort. One hundred thirty-one patients
were scanned on the 1.5-T scanner before August
2006. Nineteen (6.7%) patients required sedation
for the CMR scan, among them 2 patients requiring
intravenous conscious sedation (because oral agents
were not effective). Sixteen (5.6%) required scan-
ning using a wide-bore scanner, among them
4 patients requiring oral sedation and 1 requiring
intravenous sedation. Of the overall population,
24 (8%) had atrial ﬁbrillation, and 3 of 24 had
nondiagnostic perfusion studies and were excluded
from the study.
Baseline characteristics. Patient and CMR charac-
teristics for the entire study cohort and stratiﬁed by
inducible ischemia are shown in Tables 1 and 2,
respectively. Primary indications for CMR included
suspicion of cardiac ischemia in 80% and evaluation
of suspected cardiac dyspnea in 20%. The overall
study cohort (mean age 56 years, 40% female) had a
mean BMI of 35.4  4.8 kg/m2. The maximum
weight successfully scanned was 200 kg (440 lbs).
The majority of patients were in sinus rhythm
(92%), whereas 21 patients were in atrial ﬁbrillation
during stress CMR. Patients with no evidence of
inducible ischemia by CMR had a higher BMI
(35.8  5.3 kg/m2 vs. 34.4  3.4 kg/m2, p < 0.05),
and lower prevalence of history of heart failure (14%
vs. 27%, p < 0.05), symptomatic angina (44% vs.
22%, p < 0.001), prior MI (7% vs. 36%, p <
0.0001), or prior coronary artery bypass surgery
(2% vs. 16%, p < 0.001).
The overall study cohort had a median left ven-
tricular ejection fraction (LVEF) of 62% (IQR:
16%), left ventricular mass index of 58 g/m2 (IQR:
24 g/m2), and right ventricular ejection fraction of
55% (IQR: 12%). Patients with no evidence of
inducible ischemia on CMR had a signiﬁcantly
greater LVEF (63% vs. 57%, p < 0.001), lower left
ventricular end-systolic volume index (29 ml/m2 vs.
34 ml/m2, p < 0.05), and less frequent resting wall
motion abnormalities (14% vs. 47%, p < 0.0001).
In those patients with evidence of infarction by
LGE imaging, infarct size was not different with
Table 2. CMR Characteristics for All Patients and Patients With and Without
Inducible Ischemia
Inducible
Ischemia L
(n [ 180)
Inducible
Ischemia D
(n [ 75) p Value
RV ejection fraction, %, median (IQR) 54 (12) 55 (12) 0.64
RV end-diastolic volume index, ml/m2 68 (20) 64 (14) <0.05
RV end-systolic volume index, ml/m2,
median (IQR)
31 (13) 28 (10) <0.05
LV ejection fraction, %, median (IQR) 63 (14) 57 (22) <0.001
LV end-diastolic volume index, ml/m2,
median (IQR)
79 (27) 81 (37) 0.27
LV end-systolic volume index, ml/m2,
median (IQR)
29 (20) 34 (39) <0.05
LV mass index, g/m2, median (IQR) 58 (24) 58 (24) 0.69
Resting wall motion abnormality 26 (14) 35 (47) <.0001
Presence of LGE, % 38 (21) 50 (67) <.0001
LGE mass, g, median (IQR)* 10.4 (17.7) 10.3 (15.4) 0.18
Number of segments with inducible ischemia 0.0  0.0 4.8  4.2 <0.0001
Values are median (interquartile range), n (%), or mean  SD. *In patients with LGE presence consistent
with infarction.
Abbreviations as in Table 1.
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467respect to the presence or absence of inducible
ischemia.
Clinical outcomes. Median follow-up was 2.1 (IQR:
2.8 years) years, with no loss to follow-up in the
patients studied. In the entire cohort, there were
19 deaths of any cause (7 cardiovascular [37%]). In
addition, 7 patients experienced nonfatal MI during
study follow-up. For the whole-study cohort, annu-
alized event rates were 2.2% for MACE, 4.0% for a
composite of all-cause mortality and MI, and 3.1%
for all-cause mortality alone. The annualized event
rates for MACE and composite of all-cause mor-
tality and MI by presence of inducible ischemia
and LGE are shown in Figure 2. Patients with no
evidence of inducible ischemia or infarction by
LGE had a very low annualized rate of MACE
(0.3%). Patients with LGE without inducible
ischemia experienced a higher annualized rate of
MACE (2.4%), which was signiﬁcantly lower
than those patients with presence of inducible
ischemia, but no evidence of LGE (2.4% vs. 6.3%,
p < 0.0001). The annualized rate of MACE for
patients with both inducible ischemia and LGE
was highest, at 6.7%.
Prognostic value of stress CMR in obese patients.
Univariable analysis of patient and CMR charac-
teristics for association with MACE, and all-cause
mortality/nonfatal MI are displayed in Table 3.
Age, history of diabetes, prior MI, LVEF, presence
of resting wall motion abnormalities, LGE, and
inducible ischemia were all signiﬁcantly associ-
ated with MACE in univariable Cox models.Figure 2. Annualized Rate of MACE and Composite of All-Cause Mort
Annual event rates for the entire study cohort (N ¼ 255) of major adve
infarction [MI]) and composite of all-cause mortality are shown stratiﬁed
(LGE) by stress perfusion cardiac magnetic resonance.Kaplan-Meier event-free survival curves for
MACE (primary outcome) or all-cause mortality/
nonfatal MI (secondary outcome) stratiﬁed by
inducible ischemia are shown in Figure 3. Obese
patients with inducible ischemia had a signiﬁcantly
lower event-free survival for both primary and
secondary outcomes as compared with patients
without inducible ischemia (p < 0.0001 andality and MI Stratiﬁed by Inducible Ischemia and Presence of LGE
rse cardiac events (MACE) (cardiovascular [CV] death and myocardial
by presence of inducible ischemia and late gadolinium enhancement
Table 3. Univariable Analysis of Clinical and CMR Characteristics for Prediction of Adverse Events
MACE All-Cause Mortality D MI
LR Chi-Square
Hazard Ratio
(95% CI) p Value LR Chi-Square
Hazard Ratio
(95% CI) p Value
Age 4.58 1.05 (1–1.11) <0.05 6.31 1.05 (1.01–1.08) 0.012
Female 0.02 1.08 (0.37–3.12) 0.89 0.07 0.90 (0.41–1.98) 0.79
Body mass index 0.82 0.94 (0.81–1.08) 0.36 1.24 0.94 (0.85–1.05) 0.27
Hypertension 2.89 5.84 (0.76–44.66) 0.09 0.21 1.23 (0.52–2.92) 0.65
Diabetes mellitus 6.79 4.68 (1.47–14.95) <0.01 1.47 1.61 (0.75–3.49) 0.23
Hypercholesterolemia 1.38 2.15 (0.6–7.71) 0.24 2.30 0.55 (0.25–1.20) 0.13
Smoking 0.56 1.56 (0.49–4.97) 0.46 4.83 2.43 (1.10–5.36) 0.03
Diamond Forrester pre-test probability of CAD 2.97 1.02 (1–1.04) 0.09 4.20 1.02 (1.00–1.03) 0.04
Prior MI 14.20 7.68 (2.66–22.19) <0.001 7.89 3.23 (1.42–7.31) 0.005
Prior PCI 8.36 4.7 (1.65–13.41) <0.01 1.90 1.85 (0.77–4.43) 0.17
Prior CABG 0.94 2.1 (0.47–9.4) 0.33 0.78 1.72 (0.51–5.77) 0.38
LBBB 3.75 3.54 (0.99–12.75) 0.05 0.88 1.78 (0.53–5.97) 0.35
Presence of Q waves 3.76 3.15 (0.99–10.06) 0.05 1.80 1.96 (0.73–5.22) 0.18
ST-segment changes at baseline 9.91 5.59 (1.91–16.3) <0.01 5.45 2.85 (1.18–6.87) 0.02
LV ejection fraction 4.35 0.97 (0.94–1) <0.05 2.06 0.98 (0.96–1.01) 0.15
LV mass index 7.43 1.03 (1.01–1.05) <0.01 2.19 1.01 (1.00–1.03) 0.14
LVESVI 5.47 1.02 (1–1.03) <0.05 2.30 1.01 (1.00–1.02) 0.13
Resting WMA 10.65 7.11 (2.19–23.11) <0.01 7.17 2.92 (1.33–6.41) 0.007
Any stress perfusion defect 9.84 25.93 (3.39–198.24) <0.01 10.29 3.76 (1.67–8.43) 0.001
Revascularization within 60 days of CMR 4.93 3.46 (1.16–10.34) <0.05 0.67 1.50 (0.57–3.99) 0.41
LGE 4.61 6.56 (1.18–36.5) <0.05 0.87 1.61 (0.59–4.38) 0.35
RVEF 3.54 0.95 (0.9–1) 0.06 1.49 0.97 (0.93–1.02) 0.22
Presence of inducible ischemia 12.28 9.81 (2.74–35.19) <0.001 10.665 3.66 (1.68–7.97) 0.001
CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; LBBB ¼ left bundle branch block; LR chi-square ¼ chi-square likelihood ratio; LVESVI ¼ left ventricular end-systolic volume
index; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; RVEF ¼ right ventricular ejection fraction; WMA ¼ wall motion abnormality; other abbreviations as in
Table 1.
Figure 3. Kaplan-Meier Survival Curves Stratiﬁed by Presence of Inducible Ischemia
Kaplan-Meier survival curves for MACE (CV death and MI) stratiﬁed by presence of inducible ischemia by stress perfusion CMR. Abbreviations
as in Figures 1 and 2.
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Figure 4. Kaplan-Meier Survival Curves for Patients With No LGE, Stratiﬁed by Presence of Inducible Ischemia
Kaplan-Meier survival curves of patients with no evidence of prior MI determined by any presence of subendocardial LGE on CMR for MACE
(CV death and MI), stratiﬁed by presence of inducible ischemia. Abbreviations as in Figures 1 and 2.
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469p < 0.005, respectively). This relationship held
when patients with LGE were excluded (Fig. 4). In
a multivariable stepwise Cox regression including
clinical characteristics and CMR indexes, inducible
ischemia (hazard ratio [HR]: 7.5; 95% conﬁdence
interval [CI]: 2.0 to 28.0; p ¼ 0.002) and resting
ST abnormalities (HR: 3.2; 95% CI: 1.1 to 9.5;
p ¼ 0.04) remained independently associated
with MACE. None of the time-dependent cova-
riates included in the ﬁnal multivariable Cox model
were signiﬁcant, suggesting that the proportionality
assumption was not violated.
Censoring of patients who underwent early coronary
revascularization. Of the 255 patients in the study,
32 patients underwent early coronary revasculariza-
tion (within 90 days of stress CMR). In the 223
patients remaining in the cohort after exclusion
of these patients, there were 9 MACE events
(5 nonfatal MI and 4 cardiac deaths). When these
patients were censored on the day of the early re-
vascularization, both presence of inducible ischemia
and ischemia extent per segment remained highly
associated with MACE (HR: 9.81; 95% CI: 2.74 to
35.19; p ¼ 0.0005 and HR: 1.15; 95% CI: 1.07 to
1.23; p ¼ 0.0001, respectively).
D I SCUSS ION
In this cohort of 285 obese patients clinically
referred for stress CMR, we found that stress
CMR produced diagnostic quality imaging in
more than 89% of patients. Despite lingering
concerns over claustrophobia, only 7% of obesepatients required sedation to achieve a diagnostic
CMR. CMR inducible ischemia was a strong,
independent predictor of MACE in multivariable
models, with lack of inducible ischemia or LGE
associated with a low annual MACE rate of 0.3%.
Collectively, these results suggest that stress
CMR is highly feasible and has excellent prog-
nostic utility in obese patients.
Cardiovascular disease in obese patients repre-
sents a unique challenge for clinicians, especially
in light of technical limitations inherent to cur-
rent, widely utilized methods of risk stratiﬁcation
(e.g., nuclear, echocardiographic, treadmill stress
testing, or computed tomography angiography).
Despite the growing at-risk obese population,
current literature examining the prognostic im-
portance of stress echocardiography and nuclear
imaging in this population remains limited. Al-
though a negative dobutamine stress echocardio-
gram carries an annualized rate of cardiac MACE
of 1.3% in a general referral population (17), the
prognostic performance of dobutamine stress
echocardiography in obese patients is not widely
known. With regard to nuclear imaging, Elhendy
et al. (18) reported on the prognostic importance
and feasibility of dobutamine 99mTc-tetrofosmin
SPECT imaging without attenuation correction in
267 obese patients (mean BMI 37 kg/m2) with a
similar risk proﬁle as our study. These authors
demonstrated signiﬁcant breast or diaphragmatic
attenuation in 40 patients (16%) leading to non-
diagnostic stress perfusion in 6 (2%). This technical
limitation is not experienced with stress perfusion
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470CMR. At a mean follow-up of 5.5 years, 22 cardiac
deaths were observed, with an annualized rate of
cardiac death and MI of 1% in patients with normal
perfusion, signiﬁcantly higher than observed with
stress CMR. Importantly, abnormal nuclear stress
perfusion was a strong univariate and multivariate
predictor of MACE in this study. Although the
authors suggest that attenuation correction may
have improved stratiﬁcation of risk in obese pa-
tients, the high annual MACE rate and the frequent
presence of imaging artifacts with SPECT methods
may more accurately reﬂect real-world clinical
practice. Finally, computed tomography angiog-
raphy (CTA) has emerged as a useful modality to
assess for obstructive CAD, with high diagnostic
accuracy (8,19). Indeed, in a study of more than
13,000 patients, BMI was strongly associated with
the extent of obstructive CAD at CTA (20).
Despite these excellent results, however, CTA re-
quires radiation exposure, and its diagnostic per-
formance may be limited by a low signal-to-noise
ratio in the obese population.
The prognostic importance of negative nuclear
myocardial perfusion imaging has been shown to
be associated with BMI. In a retrospective study
of 433 patients with a signiﬁcantly higher BMI
(47.3 kg/m2) with exercise or vasodilator 99mTc
SPECT, Duvall et al. (9) reported that despite
having only 2% poor-quality scans, patients with
normal perfusion had up to a 3.7% risk of death at
2 years, and 1.7% risk of death at 1 year, higher
than stress perfusion CMR in our study. Impor-
tantly, 82Rb-PET has also shown high diagnostic
and prognostic performance in obese patients. In
a landmark study of 134 obese patients referred
for clinically indicated dipyridamole 82Rb-PET,
patients with normal PET perfusion had a 0% car-
diac event rate at a mean 3.1-year follow-up (10),
signiﬁcantly better than SPECT imaging. These
ﬁndings are comparable to our reported results for
stress perfusion CMR. In addition to ischemia,
however, the improvements in spatial resolution with
CMR allow detection of small subendocardial MI
that is prognostically important, without ionizing
radiation (21).
Our results in an obese population are in keeping
with recent large reports in overall referral pop-
ulations attesting to the prognostic role of stress
CMR (22,23), suggesting the generalizability of
standard perfusion techniques to obese patients. In a
recent large study involving dobutamine stress
CMR in 3,138 patients, Kelle et al. (23) describe
complementary prognostic information from wall
motion abnormalities and LGE, though data onaverage BMI in this cohort was not provided.
These results have been conﬁrmed in a large recent
meta-analysis (22). Our work extends the aggregate
data in stress CMR by demonstrating its prognostic
utility speciﬁcally in patients with obesity, in whom
imaging methods are limited, with potentially
nonspeciﬁc results (21). Moreover, we also conﬁrm
in an obese population that inducible ischemia and
LGE by stress perfusion CMR are robust markers
of risk even in those patients without a clinical
history of prior infarction, in keeping with prior
reports suggesting the prognostic importance of
LGE in patients with clinically unrecognized MI
(24,25). In addition, as technical developments
increasing the ﬁeld strength possible with open
magnetic resonance imaging systems emerge, the
possibility of further application of stress perfu-
sion CMR in obese patients may become more
generalizable.
Study limitations. The results of our study must
be taken in the context of its design. The relatively
low event rate in our study reduces the number of
clinical and CMR parameters that may be evaluated
in multivariable modeling. Despite the low number
of events, this event rate and our patient risk proﬁle
are comparable to similar studies in the nuclear
literature. Even with this low overall rate of MACE,
the absence of inducible ischemia and LGE still
identiﬁed patients with a dramatically low rate of
MACE. Over the 10-year study period, both 1.5-
and 3.0-T ﬁeld strengths were used for stress
perfusion imaging. It should be noted that the
proportion of nondiagnostic scans were similar at
6% between 1.5- and 3.0-T. Therefore, although
our imaging protocol was tailored to obese patients,
the methods used to optimize cine, perfusion, and
LGE imaging were found to be highly transportable
across scanner platforms and ﬁeld strengths, sug-
gesting this was not a signiﬁcant limitation to
generalizability. In addition, given the increasing
adoption of 3.0-T scanners worldwide for CMR, it
is likely that image quality and standardization will
continue to improve. Although we report in the
current study that a negative CMR is associated
with a very low annualized rate of cardiac events,
comparison of prognostic utility of CMR between
obese and nonobese patients is not possible on the
basis of the current evidence. Finally, although the
determination of a threshold extent of inducible
ischemia is a clinically important question, the
limited number of events in this select popula-
tion does not allow us to calculate this threshold,
although other studies in nuclear and stress CMR
have examined this important question (26,27).
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471CONCLUS IONS
Stress CMR is feasible in an obese population, and
absence of ischemia or myocardial scar is associated
with very low MACE in long-term follow-up. With a
growing population of obese patients at signiﬁcant risk
for cardiovascular disease, these results suggest the useof stress CMR to stratify risk in symptomatic obese
patients with suspected CAD may be warranted.
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